{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:32:26Z","timestamp":1777901546719,"version":"3.51.4"},"reference-count":164,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijrobp.2025.02.022","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T11:07:06Z","timestamp":1740827226000},"page":"294-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Moving From the Background Toward the Spotlight: A Critical Review of Radiation Therapy for Locally Advanced Pancreas Cancer"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-7518","authenticated-orcid":false,"given":"Michael D.","family":"Chuong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishan","family":"Jethwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Kharofa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Koay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bailey","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.02.022_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0002","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0003","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1245\/s10434-024-15443-1","article-title":"Radiologic occult metastases in pancreatic cancer: Analysis of risk factors and survival outcomes in the age of contemporary neoadjuvant multi-agent chemotherapy","volume":"31","author":"Yee","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210044","article-title":"The role of radiotherapy in locally advanced pancreatic cancer","volume":"94","author":"Huguet","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0005","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"16 Suppl","key":"10.1016\/j.ijrobp.2025.02.022_bib0006","article-title":"Randomized Phase III Trial of Induction Chemotherapy Followed by Chemoradiotherapy or Chemotherapy Alone for Nonresectable Locally Advanced Pancreatic Cancer: First Results of the Conko-007 Trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0008","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO.23.01402","article-title":"Elucidating the benefit of radiation therapy in GI cancers: Rethinking trial end points and patient selection","volume":"42","author":"Sanford","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","article-title":"Yield of staging laparoscopy for pancreatic cancer in the modern era: Analysis of more than 1,000 consecutive patients","volume":"237","author":"Gudmundsdottir","year":"2023","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0010","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.gassur.2005.06.008","article-title":"CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer","volume":"9","author":"Karachristos","year":"2005","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0011","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/cncr.31251","article-title":"Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy","volume":"124","author":"Amer","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0012","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2022.06.089","article-title":"Nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in treating patients with locally advanced and borderline resectable pancreatic cancer: Phase 1 trial and imaging-based biomarker validation","volume":"114","author":"Koay","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215409","article-title":"Computational modeling of pancreatic cancer patients receiving folfirinox and gemcitabine-based therapies identifies optimum intervention strategies","volume":"14","author":"Yamamoto","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0014","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3389\/fonc.2019.01464","article-title":"Improving treatment response prediction for chemoradiation therapy of pancreatic cancer using a combination of delta-radiomics and the clinical biomarker CA19-9","volume":"9","author":"Nasief","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13014-023-02328-y","article-title":"Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy","volume":"18","author":"Jan","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0016","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00259-018-4251-5","article-title":"Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET\/CT for detecting metastases from pancreatic ductal adenocarcinoma: A proof-of-concept study","volume":"46","author":"Cheng","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170411","article-title":"Dual energy CT applications in pancreatic pathologies","volume":"90","author":"George","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0018","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the American Pancreatic Association","volume":"270","author":"Al-Hawary","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0019","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of SMAD4(DPC4) immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/SLA.0b013e31827fe9ce","article-title":"Failure patterns in resected pancreas adenocarcinoma: Lack of predicted benefit to smad4 expression","volume":"258","author":"Winter","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.radonc.2021.02.037","article-title":"High expression of Kruppel-like factor 10 or smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial","volume":"158","author":"Pen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.18632\/oncotarget.27496","article-title":"A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection","volume":"11","author":"Wolfe","year":"2020","journal-title":"Oncotarget"},{"issue":"16_suppl","key":"10.1016\/j.ijrobp.2025.02.022_bib0023","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.2023.41.16_suppl.4154","article-title":"Clinical Utility of Next Generation Sequencing (NGS) on Circulating Tumor DNA (CTDNA) in Patients (PTS) with Pancreatic Cancer (PC)","volume":"41","author":"Keane","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ijrobp.2025.02.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.636","article-title":"Frequency and Oncologic Outcomes of KRAS Mutations in Circulating Tumor DNA of Patients With Pancreatic Ductal Adenocarcinoma","volume":"42","author":"Yousef","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0025","article-title":"Targeting KRAS mutations in pancreatic cancer: Opportunities for future strategies","volume":"11","author":"Linehan","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0026","article-title":"Pd-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: A biomolecular exploratory, phase II trial","volume":"4","author":"Du","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0027","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1200\/EDBK_160827","article-title":"Localized pancreatic cancer: Multidisciplinary management","volume":"35","author":"Coveler","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0028","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(24)00223-7","article-title":"Celiac plexus radiosurgery for pain management in advanced cancer: A multicentre, single-arm, phase 2 trial","volume":"25","author":"Lawrence","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0029","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0030","doi-asserted-by":"crossref","first-page":"e7434","DOI":"10.1002\/cam4.7434","article-title":"Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the united states","volume":"13","author":"Shi","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0031","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"Folfirinox for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4506","article-title":"A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201","volume":"26","author":"Loehrer Sr","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0034","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0036","article-title":"Causes of death among patients with initially inoperable pancreas cancer after induction chemotherapy and ablative 5-fraction stereotactic magnetic resonance image guided adaptive radiation therapy","volume":"8","author":"Chuong","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0037","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0038","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2021.02.008","article-title":"Phase I trial of stereotactic body radiation therapy dose escalation in pancreatic cancer","volume":"110","author":"Courtney","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0039","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0041","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ijrobp.2025.02.022_bib0042","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2023.41.4_suppl.710","article-title":"Phase II Trial of Maximal Ablative Irradiation Because of Encasement (MAIBE) for Patients with Potentially Resectable Locally ADVANCED pancreatic Cancer","volume":"41","author":"Reyngold","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.628155","article-title":"Magnetic resonance guided radiation therapy for pancreatic adenocarcinoma, advantages, challenges, current approaches, and future directions","volume":"11","author":"Hall","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0044","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic mr-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0045","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0046","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance\u2013guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phro.2022.10.003","article-title":"Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system","volume":"24","author":"Tringale","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0048","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semradonc.2023.10.002","article-title":"The use of mr-guided radiation therapy for pancreatic cancer","volume":"34","author":"Daamen","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0049","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic mr-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0051","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0052","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S1470-2045(23)00478-3","article-title":"Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: An adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0053","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.ijrobp.2024.07.258","article-title":"Multi-institutional comparison of ablative 5-fraction mr-guided online adapted vs. 15\/25-fraction ct-guided offline adapted radiation therapy for locally advanced pancreas cancer","volume":"120","author":"Chuong","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0054","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0055","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an astro clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0056","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","article-title":"Australasian gastrointestinal trials group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT)","volume":"10","author":"Oar","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0057","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2010.0073","article-title":"Pancreatic adenocarcinoma","volume":"8","author":"Tempero","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0058","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.prro.2022.06.004","article-title":"Patterns of recurrence after primary local therapy for pancreatic ductal adenocarcinoma\u2013a critical review of rationale and target delineation for (Neo)adjuvant radiation therapy","volume":"12","author":"Jethwa","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0059","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2010.04.058","article-title":"Pancreatic cancer tumor size on CT scan versus pathologic specimen: Implications for radiation treatment planning","volume":"80","author":"Arvold","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.radonc.2012.07.004","article-title":"Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: Implications for radiation therapy planning","volume":"104","author":"Qiu","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0061","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archsurg.1985.01390320023003","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser","year":"1985","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0062","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the eortc gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0063","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0064","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0065","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"Conko-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: A multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0066","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","article-title":"Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial","volume":"299","author":"Regine","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0067","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0068","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0069","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0070","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0071","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jjco\/hyi234","article-title":"A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer","volume":"36","author":"Kosuge","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0072","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","article-title":"A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer","volume":"101","author":"Ueno","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0073","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of s-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0074","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MPA.0b013e31818166e6","article-title":"Nerve plexus invasion in pancreatic cancer: Spread patterns on histopathologic and embryological analyses","volume":"37","author":"Makino","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrc3131","article-title":"Perineural invasion and associated pain in pancreatic cancer","volume":"11","author":"Bapat","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0076","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/RCT.0b013e3181dd5bfc","article-title":"Arterial anatomy of the pancreas. Part 3: Segmented computed tomography-angiography mapping of perineural invasion","volume":"34","author":"Collins","year":"2010","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0077","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2214\/AJR.09.3285","article-title":"Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: Evaluation with 3D volume-rendered MDCT imaging","volume":"194","author":"Deshmukh","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0078","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00006676-200310000-00005","article-title":"Innervation of the pancreas from the perspective of perineural invasion of pancreatic cancer","volume":"27","author":"Yi","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0079","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4329\/wjr.v4.i2.36","article-title":"CT and MR imaging patterns for pancreatic carcinoma invading the extrapancreatic neural plexus (part I): Anatomy, imaging of the extrapancreatic nerve","volume":"4","author":"Zuo","year":"2012","journal-title":"World J Radiol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4329\/wjr.v4.i1.13","article-title":"CT and MR imaging patterns for pancreatic carcinoma invading the extrapancreatic neural plexus (part II): Imaging of pancreatic carcinoma nerve invasion","volume":"4","author":"Zuo","year":"2012","journal-title":"World J Radiol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0081","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00261-017-1343-9","article-title":"Extrapancreatic perineural invasion in pancreatic adenocarcinoma","volume":"43","author":"Patel","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0082","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006676-200404000-00002","article-title":"Pancreatic cancer registry in Japan: 20 years of experience","volume":"28","author":"Matsuno","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0083","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-5-28","article-title":"Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: A pooled analysis of clinical evidence","volume":"5","author":"Sun","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0084","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","article-title":"Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0086","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijrobp.2021.07.1698","article-title":"Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation","volume":"112","author":"Miller","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0087","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: Implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0088","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after folfirinox for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0089","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0090","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ijrobp.2012.01.022","article-title":"Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer","volume":"83","author":"Goodman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0091","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.prro.2022.01.005","article-title":"Location, location, location: What should be targeted beyond gross disease for localized pancreatic ductal adenocarcinoma? Proposal of a standardized clinical tumor volume for pancreatic ductal adenocarcinoma of the head: The \u201ctriangle volume\u201d","volume":"12","author":"Hill","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0092","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ijrobp.2023.06.231","article-title":"Patterns of locoregional failure after ablative 5-fraction stereotactic mr-guided on-table adaptive radiation therapy for pancreatic cancer","volume":"117","author":"Chuong","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0093","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: A new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0094","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"Estro acrop guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0096","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0097","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/COC.0000000000000726","article-title":"Comparison of radiation treatment volumes for borderline resectable pancreatic cancer in contemporary clinical trials","volume":"43","author":"Bluemel","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0098","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0099","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fphar.2013.00056","article-title":"Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy","volume":"4","author":"Tamburrino","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0100","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by fak inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0101","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2021.04.001","article-title":"Radiation-induced autophagy in human pancreatic cancer cells is critically dependent on g2 checkpoint activation: A mechanism of radioresistance in pancreatic cancer","volume":"111","author":"Suzuki","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0102","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-17-3435","article-title":"Smad4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0103","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2015.07.018","article-title":"Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer","volume":"117","author":"Strom","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0104","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a parp-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0106","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","article-title":"Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer","volume":"119","author":"Chan","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0108","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0109","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CHECKPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0110","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/j.prro.2023.11.011","article-title":"A multi-institutional safety and feasibility study exploring the use of hydrogel to create spatial separation between the pancreas and duodenum in patients with pancreatic cancer","volume":"14","author":"Narang","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0111","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijrobp.2024.03.034","article-title":"Upping the ante in the treatment of gastrointestinal cancer","volume":"120","author":"Miller","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0112","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0113","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jso.24538","article-title":"Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?","volume":"115","author":"Xia","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.anndiagpath.2011.08.005","article-title":"Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis","volume":"16","author":"Zhao","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0116","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1007\/s00330-023-10381-0","article-title":"Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis","volume":"34","author":"Bilreiro","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0117","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","article-title":"FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable\/locally advanced pancreatic adenocarcinoma","volume":"20","author":"Abdelrahman","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0118","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2214\/AJR.20.24567","article-title":"Borderline resectable and locally advanced pancreatic cancer: FDG PET\/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival","volume":"217","author":"Panda","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0119","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s12149-021-01629-0","article-title":"The role of FDG PET\/CT or PET\/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: A systematic literature review","volume":"35","author":"Evangelista","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0120","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1245\/s10434-020-08205-2","article-title":"The agitg gap study: A phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer","volume":"27","author":"Barbour","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0121","article-title":"Computed tomography-based biomarker outcomes in a prospective trial of preoperative folfirinox and chemoradiation for borderline resectable pancreatic cancer","volume":"3","author":"Koay","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0122","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1078-0432.CCR-20-1746","article-title":"Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis","volume":"27","author":"Yin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0123","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","article-title":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","volume":"23","author":"Pietrasz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0124","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2017.479","article-title":"KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: A retrospective study","volume":"118","author":"Nakano","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bjc.2016.175","article-title":"Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer","volume":"115","author":"Hadano","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0126","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1038\/s41598-017-08297-z","article-title":"Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer","volume":"7","author":"Del Re","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0127","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with c225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2007.04.006","article-title":"Egfr-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms","volume":"83","author":"Baumann","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0129","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (tarceva)","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0130","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cellsig.2006.03.010","article-title":"Epidermal growth factor receptor and DNA double strand break repair: The cell's self-defence","volume":"18","author":"Szumiel","year":"2006","journal-title":"Cell Signal"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-09-1324","article-title":"Radiosensitization of epidermal growth factor receptor\/her2-positive pancreatic cancer is mediated by inhibition of akt independent of ras mutational status","volume":"16","author":"Kimple","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0132","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ijrobp.2008.02.062","article-title":"Su11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation","volume":"71","author":"Cuneo","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0133","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1535-7163.MCT-12-0098","article-title":"Cotargeting mapk and pi3k signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer","volume":"11","author":"Williams","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0134","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1080\/15384101.2015.1104437","article-title":"Mek inhibitor gsk1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways","volume":"14","author":"Estrada-Bernal","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2017.05.015","article-title":"A combinatorial strategy using yap and pan-raf inhibitors for treating kras-mutant pancreatic cancer","volume":"402","author":"Zhao","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0136","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-17-3435","article-title":"Smad4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0137","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.1158\/0008-5472.CAN-06-2565","article-title":"Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress","volume":"66","author":"Kirshner","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0138","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/sj.onc.1208443","article-title":"Tgfbeta1\/smad3 counteracts brca1-dependent repair of DNA damage","volume":"24","author":"Dubrovska","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0139","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1541-7786.MCR-06-0081","article-title":"The tumor suppressor klf11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer","volume":"4","author":"Buck","year":"2006","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/emboj\/21.5.1219","article-title":"Functional proteomics of transforming growth factor-beta1-stimulated mv1lu epithelial cells: Rad51 as a target of tgfbeta1-dependent regulation of DNA repair","volume":"21","author":"Kanamoto","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0141","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1093\/nar\/gkab1184","article-title":"Loss of med12 activates the tgfbeta pathway to promote chemoresistance and replication fork stability in brca-deficient cells","volume":"49","author":"Jackson","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0142","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030527","article-title":"Radiosensitizing pancreatic cancer with parp inhibitor and gemcitabine: An in vivo and a whole-transcriptome analysis after proton or photon irradiation","volume":"13","author":"Waissi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0143","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial efficacy of olaparib with radiation and atr inhibitor requires parp1 protein in homologous recombination-proficient pancreatic cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167272","article-title":"Effects of combined treatment with ionizing radiation and the parp inhibitor olaparib in brca mutant and wild type patient-derived pancreatic cancer xenografts","volume":"11","author":"Lohse","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.749490","article-title":"DNA damage repair deficiency in pancreatic ductal adenocarcinoma: Preclinical models and clinical perspectives","volume":"9","author":"Stoof","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0146","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9081024","article-title":"Therapeutic potential of parp inhibitors in the treatment of gastrointestinal cancers","volume":"9","author":"Alhusaini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0147","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0148","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","article-title":"4,5-diarylisoxazole hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer","volume":"51","author":"Brough","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0149","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1391.012","article-title":"Drugging the cancer chaperone hsp90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress","volume":"1113","author":"Workman","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0150","first-page":"193","article-title":"Hsp90 inhibitors: Clinical development and future opportunities in oncology therapy","volume":"13","author":"Gao","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0151","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0152","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1535-7163.MCT-20-1103","article-title":"Radiosensitizing pancreatic cancer via effective autophagy inhibition","volume":"21","author":"Yazal","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0153","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030426","article-title":"Autophagy contributes to metabolic reprogramming and therapeutic resistance in pancreatic tumors","volume":"11","author":"Reyes-Castellanos","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0154","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2021.04.001","article-title":"Radiation-induced autophagy in human pancreatic cancer cells is critically dependent on g2 checkpoint activation: A mechanism of radioresistance in pancreatic cancer","volume":"111","author":"Suzuki","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216782","article-title":"Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia","volume":"588","author":"Chintamaneni","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0156","first-page":"15","article-title":"Hypoxia, a targetable culprit to counter pancreatic cancer resistance to therapy","author":"Abou Khouzam","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0157","doi-asserted-by":"crossref","first-page":"33571","DOI":"10.18632\/oncotarget.9654","article-title":"Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug th-302","volume":"7","author":"Lohse","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0158","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.1021\/acsnano.1c02283","article-title":"Synchronization of nanoparticle sensitization and radiosensitizing chemotherapy through cell cycle arrest achieving ultralow x-ray dose delivery to pancreatic tumors","volume":"15","author":"Manoharan","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0159","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512523","article-title":"Utilizing gold nanoparticles as prospective radiosensitizers in 3d radioresistant pancreatic co-culture model","volume":"24","author":"Alhussan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-022-02358-6","article-title":"Reactive oxygen species-inducing titanium peroxide nanoparticles as promising radiosensitizers for eliminating pancreatic cancer stem cells","volume":"41","author":"Salah","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0161","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a parp-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0162","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose escalation trial of the wee1 inhibitor adavosertib (azd1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0163","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","article-title":"Phase i trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer","volume":"119","author":"Chan","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.02.022_bib0164","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2217\/fon-2022-1219","article-title":"Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: Greco-2 phase ii study design","volume":"20","author":"Hoffe","year":"2024","journal-title":"Future Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625001622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625001622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:50:44Z","timestamp":1762296644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625001622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":164,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0360301625001622"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.022","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving From the Background Toward the Spotlight: A Critical Review of Radiation Therapy for Locally Advanced Pancreas Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}